NovoCure Ltd (NASDAQ: NVCR) is -1.94% lower on its value in year-to-date trading and has touched a low of $10.87 and a high of $83.60 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NVCR stock was last observed hovering at around $13.07 in the last trading session, with the day’s gains setting it 1.57%.
Currently trading at $14.64, the stock is -2.37% and -1.31% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 11.93 million and changing 12.01% at the moment leaves the stock -29.81% off its SMA200. NVCR registered -74.88% loss for a year compared to 6-month loss of -15.13%. The firm has a 50-day simple moving average (SMA 50) of $2.46 and a 200-day simple moving average (SMA200) of -$7.05.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -10.18% gain in the last 1 month and extending the period to 3 months gives it a 8.20%, and is 7.41% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.04% over the week and 5.89% over the month.
NovoCure Ltd (NVCR) has around 1453 employees, a market worth around $1.57B and $509.34M in sales. Profit margin for the company is -40.65%. Distance from 52-week low is 34.68% and -82.49% from its 52-week high. The company has generated returns on investments over the last 12 months (-21.60%).
NovoCure Ltd quarterly earnings per share for the current quarter are estimated at -$0.42 with sales reaching $131.69M over the same period.The EPS is expected to grow by 9.68% this year, but quarterly earnings will post 5.60% year-over-year. Quarterly sales are estimated to grow 3.50% in year-over-year returns.
332 institutions hold shares in NovoCure Ltd (NVCR), with institutional investors hold 87.34% of the company’s shares. The shares outstanding are 107.08M, and float is at 96.28M with Short Float at 5.76%. Institutions hold 85.89% of the Float.
The top institutional shareholder in the company is FMR, LLC with over 15.96 million shares valued at $233.69 million. The investor’s holdings represent 14.91% of the NVCR Shares outstanding. As of Dec 30, 2023, the second largest holder is Vanguard Group Inc with 9.76 million shares valued at $142.87 million to account for 9.11% of the shares outstanding. The other top investors are Capital International Investors which holds 8.86 million shares representing 8.27% and valued at over $129.74 million, while Blackrock Inc. holds 8.21% of the shares totaling 8.79 million with a market value of $128.72 million.
NovoCure Ltd (NVCR) Insider Activity
The most recent transaction is an insider sale by GROENHUYSEN WILHELMUS CM, the company’s Chief Operating Officer. SEC filings show that GROENHUYSEN WILHELMUS CM sold 1,217 shares of the company’s common stock on Mar 04 ’24 at a price of $16.01 per share for a total of $19484.0. Following the sale, the insider now owns 0.25 million shares.
NovoCure Ltd disclosed in a document filed with the SEC on Mar 04 ’24 that Leonard Frank X (EVP, Pres., Novocure Oncology) sold a total of 840 shares of the company’s common stock. The trade occurred on Mar 04 ’24 and was made at $16.01 per share for $13448.0. Following the transaction, the insider now directly holds 0.16 million shares of the NVCR stock.
Still, SEC filings show that on Mar 01 ’24, GROENHUYSEN WILHELMUS CM (Chief Operating Officer) disposed off 2,107 shares at an average price of $16.03 for $33769.0. The insider now directly holds 252,452 shares of NovoCure Ltd (NVCR).
